We investigated pretreatment fasting glucose as a predictor of patients' important outcomes in breast and colorectal cancers undergoing targeted therapies.
introduction
The increasing understanding of molecular pathways regulating cell cycle, apoptosis, angiogenesis and invasion has provided new targets in cancer therapy [1, 2] . The biologic agents trastuzumab [a humanized blocking antibody against the human epidermal growth factor receptor 2 (HER2)/neu receptor], bevacizumab [an inhibitor against vascular endothelial growth factor (VEGF)] and cetuximab [an mAb to the epidermal growth factor receptor (EGFR)] received United States Food and Drug Administration (US FDA) approval for breast and colorectal cancer treatment [http://www.cancer.gov/ cancertopics/treatment/druginformation, (3 November 2011, date last accessed)].
The identification of biomarkers that are likely to predict which patients will achieve the best response to these agents represents a major challenge for contemporary oncologists.
The current tendency to characterize reliable predictors of response to target therapy runs in parallel with the recently emerging theme of the cross talk between different families of receptors in response to ligand activation. In these respects, extensive preclinical work supports the signaling interaction between factors related to glucose metabolism (fasting glucose, insulin-like growth factors), VEGFs and members of the erbB tyrosine kinase family, such as the EGFR and HER2 [3] [4] [5] [6] [7] [8] [9] .
Several epidemiologic studies support the role of glucose metabolism in breast and colorectal carcinogenesis. Two distinct meta-analyses of case-control and prospective cohort studies on diabetes and cancer have shown a 1.3-fold increased risk for colorectal cancer and a 1.2-fold increased risk for postmenopausal breast cancer in diabetic patients [10, 11] . In major prospective cohort studies on glucose level and cancer risk, increased glucose levels were consistently associated with an increased risk of colorectal cancer [12] . Results for breast cancer were somewhat more inconsistent. Elevated baseline glucose levels appeared to be associated with an increased risk of both pre-and postmenopausal breast cancer in Korean women, but the association of interest was exclusively confirmed in postmenopausal women in the Austrian study and in premenopausal women in the Swedish study [13] [14] [15] .
Experimental data substantiate the hypothesis that increases in blood glucose and factors related to its metabolism could affect carcinogenesis through effects on cellular energy metabolism. Abnormalities in glucose metabolism can turn into enhanced sensitivity to oxidative stress and mitochondrial dysfunction [16] [17] [18] [19] . The resulting imbalance between the production of highly reactive molecular species, chiefly oxygen and nitrogen, and antioxidant defenses may significantly affect cancer risk, particularly in neoplasms with a strong metabolic component such as breast and colorectal cancers [20] .
The aim of the present study was to investigate whether, in patients diagnosed with breast or colorectal cancers, circulating levels of pretreatment fasting glucose were predictive of resistance to targeted agents. Our working hypothesis was that an association between lower levels of the investigated biomarker and longer time to disease progression might exist in these patients.
patients and methods

study participants and setting
This study was a multidisciplinary investigation coordinated by the Italian National Cancer Institute Regina Elena in Rome together with La Sapienza University in Rome. The Division of Medical Oncology B at Regina Elena and the Department of Senology at G. Pascale provided data for breast cancer patients. The Department of Medical Oncology and Endocrinology at Federico II Medical School in Naples and the Department of Colorectal Medical Oncology at G. Pascale contributed data for colorectal cancer patients.
We included participants aged ≥18, diagnosed with histologically confirmed breast or colorectal cancer and who were treated with targeted agents from 1998 to 2009. Breast cancer patients were considered suitable for inclusion if they had received trastuzumab according to the indications released by the US FDA [http://www.cancer.gov/cancertopics/druginfo/fdatrastuzumab, (3 November 2011, date last accessed)]. We posed no restrictions regarding trastuzumab use in early, locally advanced or metastatic breast cancer, neither did we in reference to the administration schedule. We included women who received trastuzumab as a single agent or in combined regimens, at any dosage and duration. Women who received trastuzumab repeatedly, either according to the same or different schedules, were considered exclusively in reference to the first use of this drug.
We further included colorectal cancer patients who had received bevacizumab and/or cetuximab according to the indications and recommendations established by the US FDA [http://www.cancer.gov/ cancertopics/druginfo/fda-bevacizumab, http://www.cancer.gov/ cancertopics/druginfo/fda-cetuximab, (3 November 2011, date last accessed)]. Again, we posed no restrictions regarding the administration schedule. Patients who first received bevacizumab and were subsequently treated with cetuximab (or vice versa) were included in our database in reference to the agent that was first administered. If repeatedly treated with either bevacizumab or cetuximab, patients were considered exclusively in reference to the first administration. We excluded patients with previous or concomitant history of malignancy other than breast or colorectal cancer, as well as patients diagnosed with either type I or type II diabetes based on laboratory data and those whose pretreatment fasting glucose was ≥126 mg/dl [21] .
data retrieving
Medical record retrieving was based on the close collaboration between a specifically trained medical assistant and the medical oncologists in charge of patient management and follow-up at the participating institutions. We reviewed the cases of breast and colorectal cancer patients diagnosed and treated between January 1998 and March 2009. For each patient, we sought to include data on demographics and anthropometrics, particularly body weight and height at baseline and at the end of follow-up. We further retrieved data on cancer features at the time of diagnosis (e.g. stage of disease), ascertainment of HER2/neu receptor status in breast cancer and EGFR and KRAS status in metastatic colorectal cancer patients, administered therapy and follow-up.
laboratory assays
Pretreatment fasting glucose was measured on venous blood collected at the time of (histologically confirmed) breast or colorectal cancer diagnosis and previous to any form of cancer therapy. Blood samples were collected in standardized conditions claiming overnight fasting and time at blood drawing between 7 and 10 am.
Glucose concentrations were locally determined using a Cobas analyzer with Roche hexokinase reagent. Central laboratories at the participating institutions were certified to an international management systems immunohistochemistry, silver in situ hybridization and FISH HER2 positivity was determined locally and defined as immunohistochemical staining of 3+ or 2+ with evidence of gene amplification at FISH. HER2 immunostaining was carried out using the polyclonal antibody A0485 (Dako, Milan, Italy). HER2 immunohistochemistry (IHC) positivity was determined according to the American Society of Clinical Oncology-College of American Pathologists (ASCO--CAP) guidelines [22] .
Silver in situ hybridization (SISH) was used to assess HER2 gene and Chr17 status (Inform HER2 DNA Probe, Inform Chr17 probe; Ventana, Roche Diagnostic, Milan, Italy). The HER2 and centromere on chromosome 17 dinitrophenol-labeled probes were visualized using the rabbit anti-dinitrophenol primary antibody and the ultraVIEW SISH Detection Kit. Case definition was carried out according to the ASCO-CAP guidelines [22] .
IHC, DNA extraction and KRAS mutation analysis
Immunohistochemical stains for EGFR were locally carried out on 5-μ paraffin-embedded tissue sections using DAKO EGFR PharmDX kit (Dako). EGFR expression was defined positive as any membrane staining above background level was visualized. Results were further interpreted according to a quantitative score.
DNA for KRAS mutation analysis was extracted using the DNA extraction kit QIAmp DNA kit (Qiagen-Explera, Jesi, Italy). The DNA was used in a PCR to amplify the region of exon 2 of KRAS-containing codons The PCR products were purified using Nucleospin Extract II Purification kit (M-Medical, Milan, Italy), sequenced using BigDye Terminator v 3.1 kit (Applied Biosystems, Monza, Italy) and analyzed with an ABI 3130 capillary electrophoresis system (Applied Biosystems). The presence of a heterozygous KRAS mutation was defined as the appearance of a mutant peak with a height of at least one-third of that of the wild type. In all the colorectal cancer patients, DNA was extracted from the primary tumor.
Extensive details on the procedures described above will be provided upon request.
statistical analyses
We examined distributions and computed descriptive statistics for all the variables of interest. We described the study participants' features (overall and by cancer site) and reported them through tertiles of pretreatment fasting glucose. We used means and standard deviations for continuous data as well as frequencies and percentage values for categorical data. Existing differences between mean values were evaluated using the Student's T or one-way analysis of variance test dependently on the number (two or more) of groups compared. We used the Pearson's Chisquare test of independence (two tailed) to assess the relationships between categorical variables.
We carried out survival analyses using the Kaplan-Meier product-limit method and applied the log-rank test to compare the survival curves through tertiles of fasting glycemia. Time to the development of resistance to targeted agents was calculated as the interval between the date at first trastuzumab/bevacizumab/cetuximab administration and (the date at) disease progression, last follow-up or death by cancer, whichever came first. We conducted survival analyses on the overall sample and on subsets obtained stratifying by cancer site, gender and, in women, menopausal status. Given the recognized role of KRAS status in predicting patients' important outcomes in metastatic colorectal cancer treated with cetuximab [23] , we conducted a set of separate analyses excluding the 46 patients with unknown KRAS status.
The Cox proportional hazards model was used to further test the predictive role of fasting glucose on patients' important outcomes in multivariate analyses. Gender, age and body mass index (BMI) at cancer diagnosis were included as covariates. The model was further stratified by primary site of cancer (i.e. breast versus colorectal cancer). We also used stage at cancer diagnosis as a proxy variable for cancer burden and tested it for interaction in a separate Cox model.
Data on age at cancer diagnosis were not available for 10 patients, while BMI was unknown for 38 patients. Missing values for these two variables were replaced by their means calculated by cancer site and tertiles of fasting glucose, respectively.
We considered P values <0.05 statistically significant. All statistical analyses were carried out with the SPSS statistical software version 18 (SPSS Inc., Chicago, IL).
results
Overall, four hundred and twenty cancer patients were included in our analyses. Two hundred and eighteen patients had received a breast cancer diagnosis, while two hundred and two patients had been diagnosed with colorectal cancer. Mean age at cancer diagnosis was 53.4 ± 12.8. Females were more represented than men (298 versus 122), as well as postmenopausal women among females (160 of 298). Participants were more commonly married (221 of 420) than separated, single or widowed. Data related to smoking status were only partly available, with current/past smokers representing 13.6% of our sample. Means and standard deviations for height (cm), weight (kg) and BMI (m 2 /kg) at baseline were 162.6 ± 7.9, 66.2 ± 13.1 and 25.5 ± 4.3, respectively. The median duration of follow-up was 20 months (1-128; data available upon request).
In Table 1 , our study participants were compared by primitive cancer site. Cancer patients significantly differed by age at cancer diagnosis, menopausal status, marital status, anthropometrics at baseline and stage at cancer diagnosis. Breast cancer patients were more likely to be younger, premenopausal and with a lower disease stage at cancer diagnosis when compared with colorectal cancer patients (49.4 ± 12.2 versus 57.8 ± 12.1, P < 0.001; 74.5% versus 25.5%, P = 0.025 and 98.8% versus 1.2%, P < 0.001, respectively). Separated, single and widowed participants were significantly more common among breast cancer patients than in the colorectal cancer group (92.9%, 76.5% and 66.7% versus 7.1%, 23.5% and 33.3%, P = 0.019, respectively). Furthermore, women diagnosed with breast cancer showed lower height and body weight at baseline (161.2 ± 6.5 versus 165 ± 9.2, P = 0.008, respectively).
Cancer patient characteristics through tertiles of pretreatment fasting glucose appear in Table 2 . Patients in the first tertile were more likely to be younger, single, female and, if so, premenopausal when compared with participants in the third tertile (48.9 ± 13.6 versus 57.5 ± 11.4, P < 0.001; 60% versus 16%, P < 0.001; 39.3% versus 27.8%, P = 0.001 and 51.9% versus 18.5%, P < 0.001; respectively). Cancer patients in the first tertile of pretreatment fasting glucose were also more commonly smokers and showed lower body weight and BMI at baseline (49.1% versus 22.8%, P < 0.001; 63.3 ± 12.9 versus 70.2 ± 12.4, P = 0.001 and 24.8 ± 4.4 versus 26.3 ± 4.1, P = 0.029, respectively). Figure 1 shows the time to disease progression through tertiles of pretreatment fasting glucose for the overall sample. At 60 months, 65% of cancer patients in the lowest tertile (≤88 mg/dl) did not experience disease progression compared with 34% in the second and third tertiles (P = 0.001). When stratifying by gender (Figure 2 ), 76% of female participants in the lowest tertile showed no progression compared with 49% in the remaining tertiles (P = 0.015). We further stratified analyses by menopausal status and primitive cancer site. In supplemental Figure S1 (available at Annals of Oncology online), premenopausal women in the lowest tertile showed a longer, although of only borderline significance, time to disease progression compared with women in the highest tertile (74% versus 39%, P = 0.053). In supplemental Figure S2 (available at Annals of Oncology online), there was an indication for longer time to disease progression in breast cancer participants with lower pretreatment glucose levels compared with breast cancer patients in the highest tertile (87% versus 54%, P = 0.053). The exclusion of the 46 colorectal cancer patients with unknown KRAS status did not affect our estimates (data available upon request).
Cox proportional hazards models of variables associated with time to disease progression in breast and colorectal cancer patients overall and by site of primitive cancer are presented in supplemental Tables S1 and S2 (available at Annals of Oncology online). As shown in Table S1 (available at Annals of Oncology online), in multivariate analysis including gender, age at cancer diagnosis and BMI as covariates, the predictive role of pretreatment fasting glucose on time to disease progression was confirmed. Cancer patients in the second and third tertiles showed a significantly shorter time to disease progression compared with those in the first tertile [hazard ratio (HR) 1.86, 95% confidence interval (CI) 1.10-3.16 and HR 1.76, 95% CI 1.01-3.08, respectively]. However, when stratified by primary site of cancer (Table S2 , available at Annals of Oncology online), the Cox model confirmed these results only in breast cancer patients in the first tertile compared with the third (HR 4.07, 95% CI 1. 29-12.85 ). The Cox model testing the interaction between stage at cancer diagnosis and pretreatment fasting glucose produced no significant results (P = 0.640).
discussion
According to the results of our historic cohort study, in breast and metastatic colorectal cancer patients treated with targeted agents, lower levels of pretreatment fasting glucose were predictive of longer time to disease progression. When stratifying by gender, pretreatment fasting glucose was a stronger predictor in women than in men. There was also a suggestion for a role of menopausal status and primitive cancer site in modifying the association of interest, with results of borderline significance in premenopausal women and in patients diagnosed with breast cancer. Our results do not support the existence of a dose-response relationship between the biomarker of interest and treatment outcome. Indeed, breast and colorectal cancer patients in the second and third tertiles showed no difference in terms of time to disease progression. Though on highly speculative ground, this seems to suggest that increases in pretreatment fasting glucose might affect treatment outcomes across a relatively restricted range of normal values. In our historical cohort, the latter range seems to fall within the first tertile (i.e. ≤88 mg/dl). Conversely, further increases do not necessarily translate into substantial worsening of the outcomes considered. Our figures seemed to suggest a relevant role of primary site of cancer on the association of interest, which was confirmed in multivariate analyses stratified accordingly. The Cox model showed a significant longer time to disease progression exclusively in breast cancer patients in the first tertile compared with the third (P = 0.017). Conversely, fasting glucose had no predictive role on time to disease progression in colorectal cancer patients. Differences in tumor burden between these two subpopulations might help explain this result. Though we lack adequate data to precisely estimate the tumor burden, based upon the stage at cancer diagnosis and indications to trastuzumab administration, we might speculate that our breast cancer patients were quite equally distributed among the early and advanced stages. Conversely, most of the colorectal cancer patients were metastatic at diagnosis and all of them were metastatic at target therapy administration. In these patients, the investigated association might have been obscured by the greater cancer burden and the consequent more rapid onset of drug resistance. However, when testing the interaction between stage at diagnosis and pretreatment fasting glucose, no significant results were obtained. The retrospective nature of our study design represents the main source of our study limitations. The retrospective design has limited us in availability of data potentially relevant to the investigated association, e.g. smoking status, number and site of metastatic involvement. This is extremely common when relying on data primarily collected for clinical purposes in a clinical setting. Furthermore, among the potential predictors of resistance to targeted agents related to glucose metabolism, we exclusively investigated fasting glucose while not considering other potentially relevant markers, such as baseline insulin, insulin-like growth factor-I (IGF-I) and insulin-like growth factor proteins. Unfortunately, no biological samples and related consent forms were available for the included participants. Finally, we based our analyses on a single pretreatment fasting glucose determination. We are conscious that glucose levels from a single serum sample may not adequately characterize the exposure of interest. On the other hand, although available, the results of further glucose determinations may have been influenced by administered treatments.
Our study also has several important strengths. First, for each of our patients, the standard assay of pretreatment fasting glucose was run by the central laboratory of the pertinent participating cancer institute. This is a major strength of our study. Indeed, institutional central laboratories have active and ongoing quality control protocols, which ensure high-quality biomarker data. Secondly, given that data were collected via retrieval of medical records, this study provided a relatively inexpensive and fast way to investigate the stated hypothesis. Abstraction from the medical records was carried out by a specifically trained medical assistant in close collaboration with the medical oncologists who had prospectively followed the patients included in our analyses. This increases our confidence in the quality of the information gathered. Furthermore, the pretreatment assessment of the exposure of interest (fasting glucose) should preserve the temporality of the observed associations, an important criterion to assess causality. Finally, we explored a completely novel and potentially highly informative relationship. Our study results are barely comparable with the currently available epidemiologic evidence. It is worthy to note that all previous research in the pertinent area, that is the impact of glucose-related metabolism on breast and colorectal carcinogenesis, has focused either on breast and/or colorectal cancer incidence and/or mortality. Among the prospective studies conducted so far, only a few found no associations [24, 25] , while the majority showed significantly increased risk of cancer development or death with increased glucose [10-15, 24, 26-37] . From a biological perspective, the interplay between factors related to glucose metabolism and the molecular targets of the therapeutic agents of interest might help interpret our study results. Indeed, data from the preclinical setting have shown that insulin promotes the transcription of several genes, including those encoding the glucose transporter GLUT1 and VEGF [3] . IGF-I increases the expression of VEGF messenger RNA and the production of VEGF protein by COLO 205 colon carcinoma cells [4] and enhances the expression of VEGF in osteoblasts [5] . In addition, evidence of the tight interplay between insulin-like growth factor-I receptor (IGF-IR) and EGFR emerges from a number of studies. IGF-1R activation is crucial for the mitogenic and transforming activity of the EGFR [6, 7] .
In conclusion, the present study provides novel evidence on the predictive role of pretreatment fasting glucose levels in the development of resistance to cancer treatment. These findings may have important clinical implications in the management and prognosis for cancer patients. In fact, if additional prospective and experimental studies corroborate our findings, two main consequences could be hypothesized. First, these patients would be subject to very tight blood sugar control. Secondly, the threshold for treatment of blood glucose would change dramatically. This could potentially affect time to disease progression and increase survival, leading the way to new avenues for exploring underlying resistance to targeted agent-based regimens.
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